It seems that the infliximab causes eczematous reactions more often than other anti-TNF-α drugs – perhaps due to its greater effectiveness in treating psoriasis (80% of patients achieving 75% or greater improvement in the psoriasis severity and area index -PASI-75- vs. 52% for etanercept, and 59% for adalimumab [74]) and in connection with more effective and rapid Th1 pathway blocking. The gene discussed is TNF; the disease is psoriasis.